B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SLC22A12

MOLECULAR TARGET

solute carrier family 22 member 12

UniProt: Q96S37NCBI Gene: 11608510 compounds

SLC22A12 (solute carrier family 22 member 12) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SLC22A12

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1morin4.2871
2mangostin4.1462
3benzbromarone4.1361
4fenofibric acid3.4029
5lesinurad2.7715
6pf 050897712.4010
7benzarone2.208
8merbarone2.087
9dotinurad1.956
10Sulfinpyrazone0.691

About SLC22A12 as a Drug Target

SLC22A12 (solute carrier family 22 member 12) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented SLC22A12 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SLC22A12 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.